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Non-response to cardiac resynchronization therapy remains a significant problem in up to 30% of patients. Multisite stimulation has emerged as a
wayof potentially overcoming non-response. This may be achieved by the use of multiple leads placed within the coronary sinus and its tributaries
(dual-vein pacing) or more recently by the use of multipolar (quadripolar) left ventricular pacing leads which can deliver pacing stimuli at multiple
siteswithin the samevein.This reviewcovers the roleofmultisitepacing including the interactionwith theunderlyingpathophysiology, thecurrent
and planned studies, and the potential pitfalls of this technology.
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Introduction
The problem of cardiac resynchronization
therapy non-response
Cardiac resynchronization therapy (CRT) is one of the most success-
ful heart failure therapies to emerge in the last 25 years and is applic-
able to 25–30% of patients with symptomatic heart failure.1 Large
randomized trials have demonstrated that CRT improves quality of
life (QoL), reduces heart failure hospitalizations and mortality, and
reverses the structural remodelling of the heart.2 Clinical response
to CRT is, however, variable with up to one-third of patients not
responding.3,4 Patient selection, inadequate delivery of cardiac resyn-
chronization, and suboptimal left ventricular (LV) lead position are all
important causes of non-response.5 The pre-requisite for response
to CRT is electrical dyssynchrony manifest on the surface electrocar-
diogram (ECG) usually as left bundle branch block (LBBB). In keeping
with this patients with narrower QRS width and non-LBBB morph-
ology fare worse in terms of CRT response.6,7 In an effort to
improve CRT response, alternative methods of CRT delivery, includ-
ing multisite pacing (MSP), have been developed. Pacing the LV from
more than one coronary sinus (CS) site simultaneously can improve
acute haemodynamic response (AHR) and medium-term outcomes.
The implantation of two separate CS leads is technically challenging
and recently introduced multipolar LV leads have the ability to
deliver MSP through a single CS LV lead.
Physiological scientific rationale
for multisite pacing
Evenamongpatients with LBBB, there is heterogeneity in the location
of conduction block and resulting LVactivationpattern.8,9 Two broad
patterns of LVactivation have been described with electroanatomical
mapping: type I activation, with slow propagation from the septum to
lateral wall, and type II activation with a U-shaped activation pattern
resulting from a line of functional conduction block. A type II activa-
tion pattern would be expected to be more amenable to correction
by LV stimulation, and indeed this pattern is associated with a favour-
able response to CRT.9 A further determinant of CRT response may
be the presence, location, and burden of myocardial scar and the pos-
ition of the LV lead with respect to these regions.10– 14 Implantation
of anLV lead in anareaofmyocardial scarmaybeassociatedwith slow
conduction and block resulting in less haemodynamic improvement
and a poor clinical outcome.15 Cardiac resynchronization therapy
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exerts its beneficial effects bymore thanonemechanism,but perhaps
the most important contributing factor is restoration of intra-LV syn-
chrony.16,17 Central to this is the rapid and uniform electrical activa-
tion of the LV. This can be accomplished in a subgroup of patients by
appropriate atrioventricular (AV) timing achieving activation of the
LV frommultiplewidely separate sites [via intrinsic conduction, trans-
septal conduction from the right ventricular (RV) pacing site, and ac-
tivation from the LV pacing site]. There is some suggestion that to
synchronize effectively, the RV and LV leads should be positioned
as far from each other as possible.18 Current strategies involve the
placement of leads ‘anatomically’ rather than using more patient-
specific physiological approaches and the site of LV lead placement
remains controversial with the final position of the LV pacing lead dic-
tated by the cardiac venous system anatomy, the performance and
stability of the pacing lead, and the absence of phrenic nerve stimula-
tion (PNS). The COMPANION19 and MADIT-CRT20 studies
showed a comparable response between lateral, anterior, or poster-
ior LV lead locations, while data fromthe REVERSE-HF21 maintain the
potential benefit of a lateral lead location. The TARGET and the
STARTER studies showed that guided placement of the LV lead
over the segment of maximal mechanical dyssynchrony and avoid-
ance of scar can improve the magnitude of reverse remodelling and
clinical outcomes.22,23
Historically, significant attention has been placed on the technical
aspects of the implant procedure, particularly the placement of the
transvenous epicardial LV lead has been critical to achieving cardiac
resynchronization. It is known that the optimal site of AHR to CRT
varies between patients and therefore may need to be individua-
lized.24–26 In an effort to improve CRT response, alternative
methods of CRT delivery, including LV endocardial and epicardial
MSP have been developed. Pacing the LV endocardially or from
more than one CS site has been shown to improve CRT
response.26 –33 Recently introduced multipolar LV leads have the
potential to deliver stimulation through multiple electrodes from a
single lead.34,35 As the benefits of CRT are predominantly thought
to result from improved LV electrical resynchronization, the
concept of MSP has arisen as an alternative strategy for improving
CRT success rate. Human data with MSP are restricted to a small
number of pacing sites due to the CS anatomy; however, animal
studies are not limited by this constraint. In the canine model,
Ploux et al.36 recently assessed the effect of MSP on haemodynamics
and electrical activation in nine anaesthetized dogs with chronic LBBB
where up to seven LV epicardial electrodes were placed. Each elec-
trodewas tested alone and in combination with the other electrodes.
Single-site LV pacing provided a significant increase in acute haemo-
dynamic measures (LVdP/dtmax) and was incrementally increased by
the addition of further pacing electrodes. Notably however, the
improvement in LVdP/dtmax was limited to conditions where
single-LV pacing provided suboptimal improvement. There is consid-
erable heterogeneity in the myocardial substrate of patients receiving
CRT, in particular in the aetiology of heart failure and the location of
conduction block within the heart that may account for variability in
CRT response.8,9 A non-contact mapping study of the underlying
myocardial substrate in patients receiving CRT37 showed that the
majority of patients with a non-ischaemic heart failure aetiology or
functional block responded to conventional single-site CRT,
whereas those with myocardial scar or the absence of functional
block often required MSP to achieve CRT response. It is possible
therefore that MSP may be required in certain subsets of patients
undergoing CRT, particularly those patients with ischaemic cardiomy-
opathy and with narrower QRS who may benefit from novel pacing
strategies.
Delivery of multisite pacing
Multiple leads
The concept of MSP using multiple leads is based on the hypothesis
that pacing at multiple points within the ventricles will improve
cardiac resynchronization. Two different pacing modalities have
been proposed using multiple leads: the first using two RV leads
and one LV lead, the second using one RV lead and two LV leads
inserted in the two separate tributaries of the CS. (Figure 1)
Yoshida et al.38 studied the acute haemodynamic benefit of triple-site
pacing with two RV leads and one LV lead compared with conven-
tional biventricular pacing in 21 patients. One RV lead was positioned
Figure 1 Anteroposterior projection of deployment of two
bipolar LV pacing leads in separate branches of the CS (anterolateral
and posterolateral) to achieve dual LV lead CRT.
What’s new?
† Non-response to CRT occurs 30% of patients.
† Multisite LV (MSLV) stimulation mayovercome non-response.
† MSLV achieved with multiple leads placed within the coronary
sinus (dual-vein pacing) or using multipolar (quadripolar) LV
pacing leads.
† Review of underlying pathophysiology, the current and
planned studies, and the potential pitfalls of MSLV.
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at the RVapexand the second in the RVoutflow tract. LVdP/dtmax and
cardiac output were significantly improved with triple-site pacing
compared with biventricular pacing. The authors also found an
acute reduction in LV end-systolic volume (LVESV) and an acute
increase in LVEF, although the differences were small. Finally, they
showed that bifocal RV and LV pacing were superior to biventricular
pacing in acutely improving mechanical dyssynchrony. The advantage
of this concept is that implantation of two RV leads may be technically
easier than twoLV leads; however, this pacingconfigurationhasyet to
be evaluated chronically in a prospective randomized trial. The use of
two LV leads was initially tested with acute haemodynamic studies
with conflicting results. Pappone et al.39 demonstrated a significant
improvement in LVdP/dtmax, pulse pressure, and LV end-diastolic
pressure with dual-site LV pacing. Padeletti, however, did not show
a significant haemodynamic improvement with dual-vein LV pacing
at the optimal AV delay if the first lead was positioned optimally.31
Ginks et al. found that dual-vein LV pacing increased LVdP/dtmax,
but that this effect was only marked in patients with posterolateral
scar.33 The feasibility of chronic implantation of two leads into the
CS has been shown with a success rate of 85–95% and encouraging
mid-term follow-up results.29,30 In a randomized crossover trial
(TRIP-HF) including 42 patients with permanent atrial fibrillation
and a CRT indication, Leclercq et al.29 showed that dual-vein LV
pacing did not improve New York Heart Association (NYHA)
class, 6 min walk test (6 MWT), and QoL comparedwith convention-
al biventricular pacing but did yield a significant improvement in LVEF
and LVESV at 3 months follow-up. Lenarczyk et al.30 in a non-
randomized study compared 27 patients with biventricular pacing
and 27 with dual-vein LV pacing and showed that the magnitude of
improvement in symptoms and LVEF was higher with dual-vein LV
pacing. The Trust CRT trial, a randomized trial including 98 patients,
showed that dual-site LV pacing significantly increased CRT response
based on the NYHA class as compared with biventricular pacing.40
Rogers et al. in a double-blind randomized crossover trial compared
MSP with conventional biventricular pacing in 43 patients.32 Two
groups were identified: Group A with two CS leads and one RV
lead and Group B with two RV leads (septum and apex) and one
LV lead. The primary endpoint was the comparison at 3 months of
6 MWTs which was significantly increased with MSP compared
with standard CRT (451+ 112 vs. 425+ 119 m, P ¼ 0.008). Inter-
estingly, a significant improvement in LVEF and LVESVs were also
observed but only in Group A. Recently, Ogano et al.41 reported a
potential antiarrhythmic effect of dual-vein LV pacing in 58 patients.
During a mean follow-up of 481 days, ventricular arrhythmias
occurred in 2 of 22 patients in the dual-site LV pacing and 14 of 36
in the standard CRT group with ventricular indices of QT, JT intervals
and transmural dispersion of repolarization significantly shortened at
6 months with dual-site LV pacing compared with standard CRT.
Multisite pacing with multiple pacing leads (dual-vein LV pacing)
could be a potential solution for patients who do not respond to con-
ventional CRT. The V3 trial42 has recruited 100 non-responder
patients randomized to triple-site pacing with addition of a second
LV lead into the CS or to a control group, with the primary endpoint
being the clinical composite score at 12 months and the results are
awaited. At present, MSP using multiple pacing leads is feasible with
a high implantation success rate and preliminary small studies have
shown encouraging results. However, the power of these studies is
limited and we do not at present have enough evidence to consider
this pacing modality as afirst-line therapy. Further prospective clinical
investigations are needed with a clearevaluation of the clinical benefit
and also the adverse events.
Multipolar leads and cardiac
resynchronization therapy
The alternative approach to deliverMSP rather thanvia multiple leads
is using a multipolar lead capable of delivering the multiple LV stimu-
lation sites (Figure 2). Quadripolar leads to pace the LV can now
deliver resynchronization therapy with the first report of human
Figure 2 Top: Anteroposterior projection. Coronary sinus angi-
ography performed with a telescopic catheter placed into a lateral
cardiac vein. Bottom: LAO 308 projection. Implantation of a quad-
ripolar LV lead using a similar approach compared with a regular
bipolar LV lead. The patient has a persistent left-sided superior
vena cava.
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use in 2010.43 Since then, there have been numerous reports on the
safety and efficacy of quadripolar leads both in single-centre44–45 and
multicentre settings.47– 49 Implant success rates have been above
95% and mid-term data confirm that quadripolar leads offer good sta-
bility with satisfactory dislodgement rates (≤3%) and stableperform-
ance in terms of pacing threshold.44– 49 High capture thresholds and
PNS still represent an important limitation to deliver CRT with
bipolar leads in up to 30% of patients and unfortunately these pro-
blems may arise at follow-up in a significant proportion of the
patients. The expression ‘electronic repositioning’ has been used
to describe the possibility to overcome these issues by device repro-
gramming, either by selecting different pacing vectors and/or by
adjusting pacing output to assure LV capture and avoiding PNS.
Despite this, a small percentage of patients (1–2%) who may need
a reintervention or worse will be deprived of resynchronization
therapy.50–52 Quadripolar leads offer evident advantages by offering
more pacing configurations (up to 17 vs. up to 6), which may alleviate
the problem of high thresholds, avoid PNS, or at least offer an
adequate safety margin (LV vs. phrenic nerve capture).53–55 Anatomy
of the coronary venous system and phrenic nerve course can some-
times be challenging and there have been cases where only one of the
multiple pacing configurations could be used56 and one failure where
no good configurations were found.57 Of note, the use of conven-
tional bipolar leads would not have solved these issues. Ohlow
et al.58 reported implant success with a quadripolar lead in 24 of 26
patients for whom at least two different attempts with conventional
biventricular leads had failed. The use of different quadripolar single-
site pacing vectors/configurations on acute CRT response has been
evaluated in small studies. Shetty et al.59 studied the AHR to LV
pacing within individual branches of the CS using a quadripolar lead
and found greater differences when pacing in different CS branches
compared with pacing along the same branch of the CS. Asbach
et al.60 studied different vector selections of a quadripolar LV
pacing lead and showed that an individually optimized configuration
gave rise to an additional absolute 10% increase LVdP/dtmax when
comparing optimal and worst vectors. Several studies have also
shown changes in LV electrical activation with a quadripolar lead.61,62
The next logical question is whether MSP using multipolar pacing
configurations can improveCRTresponse. To address this important
question, we only have preliminary data from small acute studies
(Table 1) and this type of pacing should still be considered experimen-
tal, with only preliminary results. Several small studies suggest that
maximization of CRT can be obtained through individualization of
MSP configuration with improvements in haemodynamic response
and dyssynchrony.63–65 Thibault et al.63 in an acute haemodynamic
study showed that in 72% of the patients, MSP from a quadripolar
lead improved acute systolic function compared with conventional
biventricular pacing, with stimulation from the most distal and prox-
imal electrodes most commonly yielding the greatest LVdP/dtmax.
Pappone et al.64 studied 44 patients using pressure–volume loops
and showed that MSP could significantly improve acute response
compared with conventional CRT. Rinaldi et al.65,66 in a multicentre
study showed acute improvements in dyssychrony with MSP and
more recently improvements in radial strain. A recent study by
Shetty et al.67 compared MSP using multiple CS leads (dual LV
lead), with MSP delivered via a single quadripolar lead. Notably,
there was a similar increase in LVdP/dtmax with dual-vein LV pacing
and single-vein MSP compared with conventional CRT, but this was
not statistically significant. Within individuals, however, different
methods of stimulation are optimal and may need to be tailored to
the underlying substrate. Studies using biophysical modelling have
suggested that MSP from a quadripolar lead may exert its benefit
mainly in patients with an ischaemic aetiology and LV scar.68
Potential complications and pitfalls
of multisite pacing
Although attractive from a pathophysiological view,69 dual-vein MSP
to achieve CRT is hindered by several clinical and technical issues.
Ogano et al.41 showed only 55% of patients had acute improvements
with dual-vein LV pacing compared with conventional CRT with no
difference in reverse remodelling at follow-up. This observation
emphasizes the need to identify the optimal LV lead placements for
MSP, which is currently unclear. In most studies, the great cardiac
vein41 or inferior/anterolateral veins7,28,32 were used for the
second LV lead in addition to the standard posterior-lateral vein
placement.Theoptimal placementof theLV lead variesbetween indi-
viduals25,27 and dual-vein LV lead pacing may be viewed as an attempt
to overcome the target site selection process by addressing multiple
accessible sites.
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Table 1 Studies of MPS delivered by a quadripolar
Author,
year
Number of
patients
Study type Findings
Thibault et al.
(2013)
19 (21) Acute comparative study
Measurement: invasive haemodynamic
evaluation (dP/dt)
72% of patients, MPP improved acute systolic function vs. conventional
CRT. Pacing most distal and proximal electrodes most commonly
yielded greatest LVdP/dtmax
Rinaldi et al.
(2013)
41(52) Comparative study after implant
Measurement: echocardiographic
dyssynchrony (TDI)
64% of patients MPP resulted in significant reduction in dyssynchrony vs.
conventional CRT
Pappone et al.
(2013)
44 Randomizedcomparative studyat the timeof
implant
Measurement: invasive haemodynamic
evaluation (pressure–volume loops)
Main finding: CRT with MPP can significantly improve acute LV
haemodynamic parameters assessed with PV loop measurements as
compared with conventional CRT
C.A. Rinaldi et al.10
Technical issues
Issues with multivein pacing
Dual-vein LV pacing may be expected to have a complication rate
higher than conventional CRT. The overall implant duration and
fluoroscopic exposure may be longer than for standard CRT
system implantation,40 potentially exposing the operator to the
harmful effects of ionizing radiation and the patient to an increased
risk of device infection. Reported complication rates with dual-vein
LV pacing cannotbe generalized, owing to the fact that centresunder-
taking these procedures are usually high-volume centres reporting
high success rates28,29,32,40 that may not directly translate to
smaller volume centres. In one study, the success rate to place a
second LV was 100%;41 however, in the study by Rogers et al.,32
46% of patients could not be successfully implanted with a second
LV lead. Data on short- and mid-term complications associated
with dual-vein LV pacing systems are limited with a complication
rate that may be higher than conventional CRT.29,30 In the TRIP-HF
study after a 9-month follow-up of 40 patients, the rate of complica-
tion was not negligible with 5 patients suffering from PNS, 4 patients
demonstrating lead dislodgement, and 2 patients having their CRT
system explanted because of infection.29 In a more recent study in
patients implanted with current tools and devices, the incidence of
serious complications at 1 year was comparable in patients with dual-
vein LV pacing compared with conventional CRT with no increase in
the rates of PNS or lead dislodgement.30 Indeed, it is possible that the
presence of two leads inside the CS may increase their stability froma
physical point of view compared with a single lead,70 but this needs to
be proven in larger patient populations. The median follow-up in the
four reported studies of chronic dual-vein LV pacing is
6 months,29,30,32,41 which is inadequate to assess safety in the long
term. Overall, 3 of 97 patients (3%) in these studies29,30,32,41 under-
went device removal because of pocket infection and 1 patient died
of sepsis unrelated to the device. In a pooled analysis of the three
largest studies,29,30,32 the occurrence of PNS that could not be
managed electronically contributed to the inability to place a second
LV lead in 9 of 103 patients (8.9%) The situation may be particularly
difficult tomanage in thepresenceof a lowphrenic threshold (3–4 V)
at one site coupled with a high (2–3 V) LV threshold at the other site.
The risk of LV lead dislodgement or loss of LV capture is increased
when lead repositioning to a more proximal site is required to
prevent PNS,71 a problem which may be better overcome with
multipolar leads which allow distal positioning of the lead and stimu-
lation from a proximal electrode. The avoidance of PNS could
potentially be achieved by dedicated devices with two LV ports
coupled to multipolar LV leads, that could address PNS at no com-
promise with the targeted coronary vein or LV stimulation site;72,73
however, the development of dedicated devices with more than
one ventricular port would not appear to be in the current plans of
the device companies.
Currently available CRT devices have only two ventricular ports
and to deliver dual-vein LV pacing, the two LV leads are generally
connected to the single ventricular port using a parallel bipolar
Y-connector. This type of connection results in a significant drop in
LV pacing impedance in 20% of patients30 and a large increase in
current delivery. Compared with conventional resynchronization,
the resulting high current drain will dramatically reduce the device
longevity. Moreover, Y-connectors are bulky and may predispose
to skin erosion. Effective dual-vein LV pacing may also be difficult to
confirm when performing LV pacing thresholds: a 12-lead ECG is
required to analyse the sometimes discrete QRS morphology
changes between dual- and single-vein LV lead capture.
Potential for pro-arrhythmia
The issue of the effect of CRT on arrhythmia burden is controversial,
with LVand biventricular pacing suspected to be pro-arrhythmic with
an increase in transmural heterogeneity of repolarization in some
patients,74 whereas CRT seems to have a protective effect against
ventricular arrhythmias in others.75 The effect of the increased
number of LV pacing sites is unclear. In dogs with chronic LBBB,36
multisite LV pacing with seven epicardial electrodes did not induce
ventricular arrhythmias acutely, and increasing the number of LV
sites was associated with a reduction in the duration of the corrected
QT interval. Acute studies of multisite LV pacing with a quadripolar
lead have not shown any acute ventricular arrhythmia;65 however,
long-term studies are required to demonstrate safety.
Currently, there is no evidence that dual-vein LV pacing with sep-
arate CS leads can improve further the overall success rate of CRT.
The current technology does not allow the easyuse of this technique:
the implantation is far more complex that the standard procedure
and the connection difficulties are problematic. Lack of data on long-
term complications such as loss of LV capture, premature generator
exhaustion (predisposing to device infection) due to the high current
drain, and skin issues related to increased pocket hardware prevent
us from reporting a full picture of dual-vein LV lead complications
against conventional CRT. At present, dual-vein LV pacing may be
proposed in patients with poor prognosis and limited life expectancy
or those who have not responded to standard CRT; the potential
clinical benefit, if demonstrated, may outweigh the device longevity
reduction. The use of multipolar electrodes to allow MSP may be
associated with less complications and downsides; however, we
only have very preliminary data.
Ongoing, planned studies and
future directions
Conventional CRT using quadripolar LV pacing leads and single-site
LV stimulation have been shown to be safe and reliable in the
short- and mid-term.44– 49 As with any new technology, longer-term
data are needed from ongoing studies evaluating the acute and
chronic performance of quadripolar leads.76–79 The multiple vectors
offered by multipolar leads provide more options to select the best
LV pacing configuration that allow good capture threshold and
avoid PNS and this new technology may offer benefits in terms of
CRT response. Conduction disturbance and electrical dyssynchrony
remain complex phenomena, and pacing the LV from multiple points
may prove helpful to overcome some of the issues due to scar and
areas of disturbed conduction. Multiple pacing electrodes on the
same LV lead also offer the ability to pace simultaneously and sequen-
tially from multiple LV sites. There are currently two randomized
controlled studies evaluating the efficacy of multisite LV pacing
with quadripolar leads on patient outcomes. The MultiPoint Pacing
IDE Study (NCT01786993) is a prospective, randomized, double-
blind, multicentre study conducted in the USA that will enrol up
to 506 patients with a standard CRT indication.80 Patients will be
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randomized to implantation with either a quadripolar or a standard
bipolar CRT-defibrillator (CRT-D) system. The two primary end-
points are freedom from system-related complications and percent-
age of non-responders (defined by a clinical composite score) at
9-months follow-up. The study was initiated in April 2013, and is
expected to terminate in 2015. The MOre REsponse on Cardiac
Resynchronization Therapy With MultiPoint Pacing (MORE-CRT
MPP) (NCT02006069) is a prospective, randomized, double-blind,
multicentre study that will be conducted in Europe, Canada, and
other non-US centres, enroling 1250 patients with a standard
CRT indication.81 All patients will be implanted with a CRT system
with a quadripolar lead and initially programmed to standard biven-
tricular pacing with bipolar pacing from a single vector of the lead.
At 6 months, non-responders (defined as patients with a ,15%
reduction in LVESV of compared with baseline) will be randomized
to ongoing standard bipolar stimulation or multipoint pacing with
stimulation via multiple vectors from the quadripolar lead. The
primary endpoint is the percentage of non-responders converted
to responders (.15% reduction in ESV) after a further 6 months
follow-up. The first patient was enroled in December 2013, and
the study is expected to terminate in 2017.
Fordual-veinLVpacing, aY-adapterwith two IS-1 inputs andan IS-4
output would be very useful to facilitate LV threshold measurements
and programming. Several device companies currently offer quadri-
polar LV leads (Figure 3). The variety of lead designs within or
across the different manufacturers offers solutions that may suit indi-
vidual patient venous anatomies. The connectors are all IS-4, which
means that they can be used interchangeably. However, currently
only one company has CRT-D generators currently offering MSP
from a quadripolar lead, although other manufacturers may also do
so in the future. No CRT-pacemaker device is currently capable of
delivering MSP, but this also is expected to be available in the future.
An important step will be to define how to optimize programming
of MSP, as little is known so far regarding this issue. It has been shown
that the configuration that most frequently yielded the best acute
dP/dtmax measurement was the tip + proximal electrodes (in 42%
21–20–20 mm
electrode spacing
4.8 F body
7.5 cm 4.0 cm0 cm
35.5 mm
Spiral L Spiral S Straight
4 F electrode
5.2 F body
7.5 mm
20.5 mm
12 mm
12 mm
12 mm
7.5 mm
7.5 mm
7.5 mm
Fluoro ring
Fluoro ring
Biotronik
4298 4398 4598 Quartet
21–1.3–21 mm
electrode spacing
5.1 F electrodes
4.0 F tip
4.7 F body
20–10–17 mm
electrode spacing
5.3 F body
Medtronic St Jude Medical
Boston Scientific
Figure 3 Currently available quadripolar LV leads, showing differences in lead design (reproduced/adapted and with permission from Boston
Scientific, St Jude Medical, and Medtronic).
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of patients).63 Electrical delay and changes in the QRS morphology of
surface ECG (Figure 4) may also be useful for pacing configuration.
Current devices can perform automatic measurements of RV–LV
delays for each electrode, both during RV sensing as well as RV
pacing, which takes 60–90 s. It seems logical that the electrode
with the greatestelectrical delayshouldbe included in the pacing con-
figuration, but the choice of the second LV electrode is less obvious.
Also, it is unclear whether it is best to measure the delays during RV
sensing or pacing. Another unanswered question is whether sequen-
tial pacing (i.e. delay between the two LV electrodes, and LV–RV
delay) is better than simultaneous pacing. Studies evaluating sequen-
tial biventricular pacing forconventional CRThavenotdemonstrated
superiority compared with simultaneous pacing.82– 84 Sequential
MSP may not offer any added benefit compared with simultaneous
pacing, unless other factors such as latency are to be considered in
individual patients. If the ideal pacing configuration can be determined
based upon electrical delays, it would be useful to have an algorithm
that automatically proposes the best settings to facilitate programming.
Another useful feature is automatic measurement of thresholds
to guide programming to reduce battery consumption. Quadripolar
CRT-D systems are currently able to automatically perform
thresholds from a variety of configurations and to indicate their
impact on device longevity (taking into account the impedance
measurements).
Figure 4 Twelve-lead ECGs of a patient with a quadripolar pacing lead with different programming timings. (A) Intrinsic rhythm with LBBB. (B)
Conventional CRT with stimulation froma single (distal pole) of the quadripolar catheter (D1-M2) of MPP from a quadripolar lead. (C) Top: Multisite
pacingwith two LV vectors separated by 5 ms. (D)Multisite pacingwith 50 ms delaybetween the two LV vectors.Changes in pacing configuration are
associated with a significant change in QRS morphology and duration with narrowing of QRS and loss of notching seen in chest leads.
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Summary
Non-response to CRT remains a significant problem and therefore
there will be further efforts to reduce this. Multisite pacing would
appear be one way of potentially overcoming non-response in add-
ition to other novel stimulation techniques such as LV endocardial
pacing. The venous anatomy will always be a determinant of
response, as it remains the gateway to the epicardium and thereby
a determinant of how the LV lead lies across the ventricular wall.
Whether pacing two electrodes along the posterolateral wall (apex
and mid-ventricular region) has a greater haemodynamic impact as
compared with pacing the distal electrode in the mid-ventricular
segment of the anterolateral wall and basal segment of the
posterolateral wall is unclear. The interaction between the electroa-
natomical activation pattern, myocyte response, and several other
covariates will all determine this response. It is quite likely that
there will not be a one-size-fit all response and that individualizing
the pacing strategy using outcome surrogates will be needed. Similar-
ly, the relatively small proximal-to-distal electrode spacing of ‘multi-
polar single-vein’ stimulation may be inadequate in terms of the
overall cardiac size and inter-patient differences.
Another important factor that may influence response to pacing is
the myofibrillar pattern and recognizing the ‘twisting motion’ of the
heart. Whether MSP should be confined to the epicardium alone is
another important question for the future. One could speculate
that a combination of endocardial and epicardial pacing may enable
Figure 4 Continued
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better and more physiological recruitment of the myocardium, and
could be a potential strategy in non-responders. Multipolar leads
are likely to be the way forward compared with multiple leads as
they offer a less complicated and technically more straightforward
way of delivering MSP. At present, multipolar leads have been
shown to be easily implantable and can avoid PNS and it is fair to
say that they have already become the standard of care in delivering
CRT. It should be highlighted that ‘multi-polar’ leads have been specif-
ically designed and developed, in the past years, while ‘multi-vein’ must
be considered experimental at its current state, with no dedicated in-
dustry developments in this field, neither for specific delivery needs
nor fixation in the tributaries. Whether true MSP delivered by such
leads will offer incremental benefit has been suggested albeit in small
studies with limited follow-up. Many of the studies stated use acute
haemodynamic data; the link, however, between acute haemodynamic
measures and long-term outcome is not yet proven.27,85 Whether
MSP will translate into longer-term clinical benefits is a yet unknown
and will require the results of large ongoing studies to see if such treat-
ment may offer benefit above and beyond conventional CRT.
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The role of surface electrocardiogram after complex left atrial arrhythmias’
ablation: behind electrical mechanisms
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We report of an interatrial dissociation after two
relatively limited left atrial ablations for paroxysmal
atrial fibrillation (PAF), with sinus rhythm in the
right atrium (RA) and ongoing atrial tachycardia in
the left atrium (LA). Patients suffering from PAF
are supposed to have less electrical and anatomical
remodelling, however the role of low-voltage and
scar areas with functional conduction block in
these patients is still ongoing discussion.
We report of an interatrial dissociation after
two relatively limited LA endocardial ablation pro-
cedures, performed in a 64-year-old woman for
PAF since 1 year. The patient underwent a success-
ful pulmonary vein isolation (PVI), and 3 months
later she developed symptomatic persistent AF requiring a second ablation. The patient underwent a re-PVI and limited ablation of
complex fractionated atrial electrograms in LA, including the coronary sinus (CS) region, but none septally. During ablation, AF converted
into an organized AT, resulting in two consecutive left localized re-entries, both related to a slow conduction zone within spontaneous low
voltage area. After ablation at the anterior wall, surface ECG showed a conversion into sinus rhythm, whereas intracardiac electrograms
revealed complete electric inter-atrial (left to right atrium) dissociation (Figure, panel A). Sinus rhythm in the RA was recorded at the prox-
imal CS catheter (CS ostium), while ongoing ATwas recorded from the circularmapping catheter (left atrial appendage) and from the distal
CS catheter (inferior perimitral LA) (Figure, panel B). We performed an electrical cardioversion with restoration of sinus rhythm in both
atria. During a5-month follow-up the patienthad no arrhythmia recurrences on HolterECG monitoring. However, one might question the
role of surface ECG regularly performed during her long term follow-up, since a recurrence of (only) left atrial arrhythmia would have been
unrecognizable.
The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/
Documents/the role of surface.pdf.
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